ScreenerHero
LQDALiquidia Corporation
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · liquidia.com
70.01USD-7.06%Mkt Cap: 6.74B $P/E: 53.81

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPI…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap6.74B $
Enterprise Value6.26B $
Revenue (TTM)450.91M $
Gross Profit145.08M $
Net Income (TTM)-68.92M $
Revenue/Share5.148 USD
Last Price70.01 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees216
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)53.81
P/E (Forward)12.58
PEG—
EV/EBITDA36.86
EV/Revenue13.88
P/S14.10
P/B32.44
EPS (TTM)1.32
EPS (Forward)5.65
52W Range
21.1567% of range93.61
52W High93.61 USD
52W Low21.15 USD
Profitability
Gross Margin91.64%
Oper. Margin49.81%
EBITDA Margin37.65%
Profit Margin-43.53%
ROE-154.03%
ROA-21.02%
Growth
Revenue Growth1842.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.69M $
CapEx (TTM)6.34M $
FCF Margin16.48%
FCF Yield1.10%
Net Debt-101.28M $
Net Debt/EBITDA-0.60
Balance Sheet
Debt/Equity4.42
Current Ratio2.31
Quick Ratio2.08
Book Value/Sh2.190 USD
Cash/Share3.175 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)107.75 USD
Upside (mean)+53.9%
Target Range90.00 USD – 130.00 USD
$90.00+53.9% to mean$130.00
# Analysts8
Ownership
Shares Out.89.51M
Float63.24M
Insiders12.58%
Institutions81.93%
Short Interest
Short Ratio8.4d
Short % Float16.71%
Short % Out.13.45%
Shares Short11.96M
Short (prev mo.)13.18M
Technical
SMA 5079.08 (-11.5%)
SMA 20049.04 (+42.8%)
Beta0.57
S&P 52W Chg18.16%
Avg Vol (30d)1.52M
Avg Vol (10d)2.06M
Technical Indicators
RSI (14)42.3
MACD-0.3014
MACD Signal1.7489
MACD Hist.-2.0503
BB Upper95.84 USD
BB Middle84.48 USD
BB Lower73.12 USD
BB Width26.89%
ATR (14)5.376 USD
Vol Ratio (20d)0.69x